Lv7
4820 积分 2025-03-18 加入
Nonclinical & clinical interface - extrapolation of nonclinical data to support Phase I clinical studies
3个月前
已完结
Mechanistic Projection of First‐in‐Human Dose for Bispecific Immunomodulatory P‐Cadherin LP‐DART: An Integrated PK/PD Modeling Approach
5个月前
已完结
The relationship between CXCR6+CD8+T cells and clinicopathological parameters in patients with primary biliary cholangitis
6个月前
已完结
Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH
6个月前
已完结
Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method
6个月前
已完结
Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method
6个月前
已完结
Development of bispecific T cell engagers: harnessing quantitative systems pharmacology
6个月前
已完结
Nonclinical & clinical interface - extrapolation of nonclinical data to support Phase I clinical studies
7个月前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
8个月前
已完结
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
9个月前
已完结
皖公网安备34019202002308
